ライフサイエンスコーパス: bromodeoxyuridine

1 of proliferating satellite cells labeled by bromodeoxyuridine.

2 preceded by 2 hour of pulse-labeling with 5-bromodeoxyuridine.

3 d cells expressed cyclin B1 and incorporated bromodeoxyuridine.

4 d on incorporation of the thymidine analogue bromodeoxyuridine.

5 ients studied by in vivo pulse labeling with bromodeoxyuridine.

6 confirmed by their nuclear incorporation of bromodeoxyuridine.

7 on cell production using the S-phase marker bromodeoxyuridine.

8 c segregation is tracked by incorporation of bromodeoxyuridine.

9 ch has some technical advantages over use of bromodeoxyuridine.

10 monidazole and cellular proliferation marker bromodeoxyuridine 1 h before sacrifice.

11 rough proliferation: 2.1+/-0.3% incorporated bromodeoxyuridine 2 hours after a single injection, and

12 ks 24 hours and 7 days after an injection of bromodeoxyuridine (2 and 8 days posthatch, respectively)

13 e division, all animals were inoculated with bromodeoxyuridine 24 h prior to sampling.

14 A in these glands with a different marker, 5-bromodeoxyuridine (5BrdU), resulted in the appearance of

15 In contrast, Bromodeoxyuridine analysis revealed that loss of Prdm16

16 iferation was determined by incorporation of bromodeoxyuridine and [3H]thymidine, fluorescence-activa

17 In vivo experiments, using bromodeoxyuridine and cell-specific markers, and ex vivo

18 small numbers of cells are doubly label for bromodeoxyuridine and olfactory marker protein, indicati

19 cells with combined immunohistochemistry for bromodeoxyuridine and retinal neuron and photoreceptor-s

20 on (types I and III) and incorporated more 5-bromodeoxyuridine and TUNEL staining compared with unsti

21 Distribution of bromodeoxyuridine and two additional adult neurogenesis

22 was documented by increased incorporation of bromodeoxyuridine and was attributed to the hypergastrin

23 ucleotides that are relatively large (dT and bromodeoxyuridine) and/or have a stable N-glycosylic bon

24 progastrin increased the number of CD44(+), bromodeoxyuridine+, and NUMB(+) cells, indicating an inc

25 , Ki-67, proliferating cell nuclear antigen, bromodeoxyuridine, and caspase-Glo 3/7 assays.

26 ularity were visualized using Hoechst 33342, bromodeoxyuridine, and CD31 staining, respectively.

27 analyzed by histology, for incorporation of bromodeoxyuridine, and for expression of the surface muc

28 ibutions of pimonidazole, GLUT-1 expression, bromodeoxyuridine, and Hoechst 33342 as visualized by im

29 ed thyroid cell number, the incorporation of bromodeoxyuridine, and the phosphorylation of retinoblas

30 weight ratio and showed increased numbers of bromodeoxyuridine- and phosphorylated histone H3-positiv

31 ated by a significant increase in numbers of bromodeoxyuridine- and Ulex europaeus-positive cells, bu

32 istinct detection procedures, one using anti-bromodeoxyuridine antibodies and the other using a 5-eth

33 We measured incorporation of bromodeoxyuridine as a marker of proliferation and phosp

34 Our studies using [(3)H]thymidine and bromodeoxyuridine as markers of DNA synthesis indicate t

35 and those that occur after treatment with 5-bromodeoxyuridine, as these mutations are also drastical

36 henyl)-2-(4-sulfophenyl)-2H-tet razolium and bromodeoxyuridine assay (MTS)] at doses between 0.001 an

37 henyl)-2-(4-sulfophenyl)-2H-tetr azolium and bromodeoxyuridine assays.

38 Newly produced cells were labeled by bromodeoxyuridine at approximately 1 week (P18-20) after

39 with markers of proliferation (ie, Ki-67 or bromodeoxyuridine) at estrus was significantly increased

40 Injections of the S-phase marker bromodeoxyuridine between postnatal days 3 and 14 showed

41 Using 5'-bromodeoxyuridine birth dating we established that mouse

42 By using bromodeoxyuridine birth dating, we found that the bullwh

43 Bromodeoxyuridine birth tracing and spatiotemporal track

44 By bromodeoxyuridine birthdating cells in green fluorescent

45 t 108 hours after gentamicin (36 hours after bromodeoxyuridine (BrdU) administration), as demonstrate

46 cord and label with the proliferation marker bromodeoxyuridine (BrdU) after a lesion.

47 Using the mitotic indicator bromodeoxyuridine (BrdU) and a retroviral vector, we fou

48 neurogenesis by labeling newborn cells with bromodeoxyuridine (BrdU) and confirming their neuronal l

49 injection of the DNA synthesis phase marker bromodeoxyuridine (BrdU) and killed at varying survival

50 cells in adult rats with the S-phase marker bromodeoxyuridine (BrdU) and used neuronal markers to ch

51 labeling new cells with the thymidine analog bromodeoxyuridine (BrdU) and using immunohistochemical m

52 ibitors is cytotoxic and cytostatic based on bromodeoxyuridine (BrdU) assay, propidium iodide (PI) st

53 ently we administered a cell cycle marker, 5-bromodeoxyuridine (BrdU) at early, middle or late period

54 Embryos were labeled cumulatively with bromodeoxyuridine (BrdU) delivered by an osmotic minipum

55 animals were injected intraperitoneally with bromodeoxyuridine (BrdU) every 2 hours for 12 hours, fol

56 Bromodeoxyuridine (BrdU) fate-tracing experiments demons

57 Bromodeoxyuridine (BrdU) feeding experiments demonstrate

58 etermined by labeling DNA of adult mice with bromodeoxyuridine (BrdU) for 3 days.

59 ne ([(3)H]dT) and the later developed analog bromodeoxyuridine (BrdU) have revolutionized our ability

60 Using this method, we detect 5-bromodeoxyuridine (BrdU) incorporated by Saccharomyces c

61 Immunofluorescence in situ hybridization and bromodeoxyuridine (BrdU) incorporation analysis showed t

62 ting and inflammatory cells were detected by bromodeoxyuridine (BrdU) incorporation and anti-CD45 sta

63 es, MASH1 transduction resulted in increased bromodeoxyuridine (BrdU) incorporation and clonal colony

64 Detection of proliferating cells based on bromodeoxyuridine (BrdU) incorporation and determination

65 fect of VEGFB gene knockout (KO) in mice, on bromodeoxyuridine (BrdU) incorporation and expression of

66 combination with GSK-3 inhibition to enhance bromodeoxyuridine (BrdU) incorporation and Ki-67 express

67 with controls, as assessed by hepatocellular bromodeoxyuridine (BrdU) incorporation and mitotic frequ

68 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of c

69 itor cells are in the G2/M cell cycle phase, bromodeoxyuridine (BrdU) incorporation demonstrated enha

70 he pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if e

71 5-bromodeoxyuridine (BrdU) incorporation was used to exami

72 An MTS assay, cell counts, and bromodeoxyuridine (BrdU) incorporation were used to dete

73 Cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation, and cell viabili

74 tion 18 +/- 2% above control, as assessed by bromodeoxyuridine (BrdU) incorporation, and reduced star

75 monitored in rat lens epithelial explants by bromodeoxyuridine (BrdU) incorporation.

76 nt of granule cell survival was monitored by bromodeoxyuridine (BrdU) incorporation.

77 on histone deacetylation and hepatocellular bromodeoxyuridine (BrdU) incorporation.

78 kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation.

79 t increase in proliferation as determined by bromodeoxyuridine (BrdU) incorporation; however, the abs

80 All mice were subjected to bromodeoxyuridine (BrdU) injection and sacrificed at dif

81 When evaluated 1 week after bromodeoxyuridine (BrdU) injection, approximately ten ti

82 Bromodeoxyuridine (BrdU) injections revealed an increase

83 y before euthanization, the rabbits received bromodeoxyuridine (BrdU) injections.

84 CLS expression inhibits the incorporation of bromodeoxyuridine (BrdU) into DNA, an effect proposed to

85 Bromodeoxyuridine (BrdU) is broadly used in neuroscience

86 ed rats, as determined using both cumulative bromodeoxyuridine (BrdU) labeling as well as labeling wi

87 The l-DOPA exposure decreased bromodeoxyuridine (BrdU) labeling in the lateral ganglio

88 Bromodeoxyuridine (BrdU) labeling indicated the same num

89 Bromodeoxyuridine (BrdU) labeling of cells, a marker for

90 Using bromodeoxyuridine (BrdU) labeling of newly generated cel

91 of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tiss

92 Bromodeoxyuridine (BrdU) labeling of proliferating cells

93 We then used bromodeoxyuridine (BrdU) labeling to see whether amacrin

94 Using in vivo bromodeoxyuridine (BrdU) labeling, a tubular cell popula

95 Transgene expression, bromodeoxyuridine (BrdU) labeling, and stem cell marker

96 5-Bromodeoxyuridine (BrdU) labeling, proliferating cell nu

97 he transplantation and 6-OHDA was tracked by bromodeoxyuridine (BrdU) labeling.

98 ly with a combination of both retroviral and bromodeoxyuridine (BrdU) labeling.

99 egion are actively cycling, as visualized by bromodeoxyuridine (BrdU) labeling.

100 urons, preweanlings were given injections of bromodeoxyuridine (BrdU) on postnatal day 6 (P6) or P21.

101 microscopy (EM) of adult mice that received bromodeoxyuridine (BrdU) or [3H]thymidine for several we

102 In agreement, bromodeoxyuridine (BrdU) pulse-chase analysis demonstrat

103 o approaches using incisor organ culture and bromodeoxyuridine (BrdU) pulse-chase experiments to iden

104 ed in vivo using thymidine analogues such as bromodeoxyuridine (BrdU) to label DNA synthesis during t

105 0 weekly injections of the thymidine analog, bromodeoxyuridine (BrdU) to mark new cells.

106 Forty-eight hour 5-bromodeoxyuridine (BrdU) uptake (used as an index of pro

107 se in cellular proliferation, as measured by bromodeoxyuridine (BrdU) uptake, and an increase in casp

108 Cell-cycle-associated markers consisted of bromodeoxyuridine (BrdU) uptake, and immunolabeling for

109 Bromodeoxyuridine (BrdU) was added to all the microcosms

110 Bromodeoxyuridine (BrdU) was administered (150 mg/kg x 3

111 Bromodeoxyuridine (BrdU) was administered 1 h, 2 days or

112 Bromodeoxyuridine (BrdU) was administered for various pe

113 Bromodeoxyuridine (BrdU) was administered to mice 3 days

114 virus (SIV) infection, the nucleoside analog bromodeoxyuridine (BrdU) was administered to six natural

115 Bromodeoxyuridine (BrdU) was given systemically to label

116 -CRM(197), MenC-PS, or saline; subsequently, bromodeoxyuridine (BrdU) was injected daily intraperiton

117 Bromodeoxyuridine (BrdU) was injected to label dividing

118 Bromodeoxyuridine (BrdU) was provided to mice continuous

119 ricular (icv) delivery of the mitotic marker bromodeoxyuridine (BrdU) we demonstrate that new cells a

120 By using a marker of cell division, bromodeoxyuridine (BrdU), in combination with several ma

121 ased proliferative activity assessed using 5-bromodeoxyuridine (BrdU), Ki-67, and c-Myc relative to n

122 Following incubation of damaged tissue with bromodeoxyuridine (BrdU), labeled nuclei were confined s

123 After an intraperitoneal injection of bromodeoxyuridine (BrdU), similar numbers of BrdU-positi

124 d nitrogen 337 nm UVA laser with and without bromodeoxyuridine (BrdU), the nanosecond and picosecond

125 A thymidine analogue, bromodeoxyuridine (BrdU), was added to the microcosms an

126 n this study, a non-native chemical species, bromodeoxyuridine (BrdU), was imaged within single HeLa

127 mmunolocalization of the nucleotide analogue bromodeoxyuridine (BrdU), we were able to follow replica

128 neurogenesis by intraperitoneal injection of bromodeoxyuridine (BrdU), which labels newborn neurons,

129 rease in epidermal turnover measured using a bromodeoxyuridine (BrdU)-based transit assay.

130 I-specific HDAC inhibitor valproic acid into bromodeoxyuridine (BrdU)-infused rats inhibited the incr

131 1(177-244)) resulted in a 4-fold increase of bromodeoxyuridine (BrDU)-labeled cells, suggesting that

132 reveal both internal L1 and L2 epitopes and bromodeoxyuridine (BrdU)-labeled encapsidated DNA is dep

133 ion cell nuclear antigen (PCNA)-positive and bromodeoxyuridine (BrdU)-labeled hepatocytes.

134 e substantiate here that I3 colocalizes with bromodeoxyuridine (BrdU)-labeled nascent viral genomes a

135 beta-cells from 1.5 +/- 0.3 to 4.0 +/- 0.8% bromodeoxyuridine (BrdU)-positive) beta-cells.

136 ONT) after injection with the S-phase marker bromodeoxyuridine (BrdU).

137 retain labels such as the thymidine analog 5-bromodeoxyuridine (BrdU).

138 ted proteins of RPE cells as demonstrated by bromodeoxyuridine (BrdU).

139 with halogenated thymidine analogs, such as bromodeoxyuridine (BrdU).

140 For mitotic labeling, bromodeoxyuridine (BrdU, 100 mg/kg) was administered twi

141 y was performed to measure the expression of bromodeoxyuridine (BrdU, a marker for cell proliferation

142 le adult rats were injected with one dose of bromodeoxyuridine (BrdU; 200 mg/kg), to label one popula

143 ere identified by nuclear incorporation of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).

144 Cytogenesis was examined at PD50 (through bromodeoxyuridine [BrdU] labeling) and survival of these

145 s between newly generated cells (marked with bromodeoxyuridine [BrdU]) and those expressing brain-der

146 otype of three constitutively proliferating (bromodeoxyuridine [BrdU]+) cell populations, including a

147 l proliferation as measured by the number of bromodeoxyuridine+ (BrdU+) cells (26.4%) compared with t

148 ssDNA oligonucleotides containing bromodeoxyuridine, BrdU-photoaptamers, are rapidly emerg

149 Bromodeoxyuridine (BrdUrd) immunolabeling and enzyme-lin

150 r flow cytometric analyses show pX-dependent bromodeoxyuridine (BrdUrd) incorporation in 4pX-1 cells

151 ociated beta-galactosidase activity, reduced bromodeoxyuridine (BrdUrd) incorporation, and reduced co

152 4-1BBL-stimulated OT-1 group showed enhanced bromodeoxyuridine (BrdUrd) incorporation, suggesting ong

153 Bromodeoxyuridine (BrdUrd) labeling studies showed that

154 Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2+/-1.2%], azoxymethane si

155 placebo by scanning electron microscopy and bromodeoxyuridine/CD31 labeling, respectively.

156 Flow cytometry and bromodeoxyuridine cell proliferation assays showed that

157 9cRA enhanced the proliferation of bromodeoxyuridine (+) cells in the subventricular zone (

158 llowed by Hi-C and then the destruction of 5-bromodeoxyuridine-containing strands via Hoechst/ultravi

159 ntation assays and in vivo administration of bromodeoxyuridine coupled to flow cytometry assays to as

160 Labeling of proliferating cells with bromodeoxyuridine demonstrated that the matrix keratinoc

161 cts, we have adapted an iododeoxyuridine and bromodeoxyuridine double labeling protocol for use in th

162 ) is greater for substrates that are larger (bromodeoxyuridine, dT) or have a more stable N-glycosidi

163 ment resulted in a decrease in the number of bromodeoxyuridine(+) (early), MAC387(+) (late), CD68(+)

164 ressed tdTomato+ in cardiomyocytes with rare Bromodeoxyuridine+, eGFP+ cardiomyocytes, consistent wit

165 DNA synthesis was analyzed by bromodeoxyuridine enzyme-linked immunosorbent assay.

166 ubulin-positive cells continue to label with bromodeoxyuridine even after 5 d of incubation.

167 cally labeled by sustained rather than acute bromodeoxyuridine exposure.

168 ere confirmed in short-term incubations with bromodeoxyuridine followed by CARD-FISH.

169 A separate cohort of mice received bromodeoxyuridine for detection of regeneration.

170 oliferation was measured by incorporation of bromodeoxyuridine, Foxf2 and Sfrp1 were localized by imm

171 Anti-5-bromodeoxyuridine immunolabeling revealed a significant

172 rands: lambda exonuclease digestion and anti-bromodeoxyuridine immunoprecipitation.

173 t first 8 weeks, after depletion of DCX- and bromodeoxyuridine-immunoreactive cells in the SVZ and de

174 d by increased number of cells incorporating bromodeoxyuridine in the whole population and increased

175 r labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of Thrb(PV/PV)-

176 Bromodeoxyuridine incorporation (in vivo) and p16(INK4a)

177 lls with Ki67 and newly generated cells with bromodeoxyuridine incorporation 3 months after the injec

178 levated proliferation rates as assessed by 5-bromodeoxyuridine incorporation and cell-cycle analysis.

179 se cell frequencies and phenotype by ex vivo bromodeoxyuridine incorporation and flow-cytometric anal

180 Bromodeoxyuridine incorporation and fluorescence-activat

181 Diminished bromodeoxyuridine incorporation and increased TUNEL stai

182 h-dependent GNP proliferation as measured by bromodeoxyuridine incorporation and Nmyc expression.

183 ll density 1.5-fold (P < 0.05), confirmed by bromodeoxyuridine incorporation and proportionate increa

184 on kinetics of CD8+ T cells in the spleen by bromodeoxyuridine incorporation and their infiltration o

185 e degree of mitogenesis and cell survival by bromodeoxyuridine incorporation and trypan blue exclusio

186 to high fat feeding, evidenced by increased bromodeoxyuridine incorporation and villus lengthening,

187 us (DG) in the mdx mouse model of DMD, using bromodeoxyuridine incorporation as a marker of prolifera

188 e and CH157-MN cells by approximately 60% in bromodeoxyuridine incorporation assays.

189 proliferation was evaluated by detection of bromodeoxyuridine incorporation by immunohistochemistry.

190 a reduction of cells in G(1), inhibition of bromodeoxyuridine incorporation during S-phase, and a mo

191 Cell proliferation was measured by bromodeoxyuridine incorporation following p21(waf1/cip1)

192 stimulated both proliferation as measured by bromodeoxyuridine incorporation in basal epidermal cells

193 it(+) cell recruitment to BZ and the rate of bromodeoxyuridine incorporation in both c-kit(+) cells a

194 typic raft cultures indicated a reduction in bromodeoxyuridine incorporation in differentiated suprab

195 EZH2 had little to no effect on apoptosis or bromodeoxyuridine incorporation in GSCs, but it disrupte

196 ear antigen and Bcl-2 expression, as well as bromodeoxyuridine incorporation in prostate cancer cells

197 anded zone of PCNA expression, and increased bromodeoxyuridine incorporation in the PTK6-deficient sm

198 Consistent with this result, bromodeoxyuridine incorporation indicated that cellular

199 WT but not KO mice, 5-HT(4) agonists induced bromodeoxyuridine incorporation into cells that expresse

200 However, the maximal level of bromodeoxyuridine incorporation is reduced in dDP mutant

201 We analyzed the cell cycle by bromodeoxyuridine incorporation or propidium iodide stai

202 Immunolocalization and bromodeoxyuridine incorporation studies of adult SGZ in

203 he S phase of the cell cycle, as assessed by bromodeoxyuridine incorporation studies.

204 higher S-adenosylmethionine levels but lower bromodeoxyuridine incorporation than control cells.

205 hromosomes protein 1 (SMC1), postirradiation bromodeoxyuridine incorporation to evaluate S phase chec

206 Furthermore, when bromodeoxyuridine incorporation was compared at 11 sites

207 In vivo bromodeoxyuridine incorporation was elevated in DTG canc

208 As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Ptt

209 Mechanical stretch-induced bromodeoxyuridine incorporation was reduced by 83.5% in

210 Inhibition of S-phase progression and bromodeoxyuridine incorporation were similarly induced b

211 sociated cushion cells displayed increased 5-bromodeoxyuridine incorporation when infected with Q79R-

212 ounts), proliferation (by flow cytometry and bromodeoxyuridine incorporation), cell viability (by try

213 nero mutations affect cell and organ size, bromodeoxyuridine incorporation, and autophagy.

214 sured using a combination of markers (Ki-67, bromodeoxyuridine incorporation, and phosphohistone H3)

215 ary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-re

216 sing a combination of in situ hybridization, bromodeoxyuridine incorporation, immunocolocalization, a

217 yte proliferation, as assessed by hepatocyte bromodeoxyuridine incorporation, phospho-histone H3 immu

218 ng independent parameters of regeneration, 5-bromodeoxyuridine incorporation, proliferating cell nucl

219 eases in the rate of cellular DNA synthesis, bromodeoxyuridine incorporation, protein synthesis, and

220 e cell (VSMC) proliferation, as reflected by bromodeoxyuridine incorporation, was markedly attenuated

221 Using bromodeoxyuridine incorporation, we show that the majori

222 the entry of cells into the cell cycle and 5-bromodeoxyuridine incorporation.

223 ctomy, and DNA replication was determined by bromodeoxyuridine incorporation.

224 roculture tetrazolium assay and by measuring bromodeoxyuridine incorporation.

225 60% increase in DNA synthesis as measured by bromodeoxyuridine incorporation.

226 is associated with a significant decrease in bromodeoxyuridine incorporation; an increase in senescen

227 ells; P < 0.01) and increased proliferation (bromodeoxyuridine incorporation; P < 0.001) of insulin-p

228 Bromodeoxyuridine-incorporation assays showed decreased

229 not parenchymal CD4(+) T cells incorporated bromodeoxyuridine, indicating local proliferation of CD4

230 kinetics were calculated using a cumulative bromodeoxyuridine injection protocol to determine the ef

231 Using bromodeoxyuridine injections at different time points du

232 nt assay (ELISA), measuring incorporation of bromodeoxyuridine into DNA.

233 There was significant incorporation of bromodeoxyuridine into smooth muscle cell DNA when treat

234 t inhibition of the in vivo incorporation of bromodeoxyuridine into the DNA of the cells in the subve

235 s well as by the diminished incorporation of bromodeoxyuridine into viral replication factories.

236 proliferation and migration, measured using bromodeoxyuridine, Ki-67, nestin, and doublecortin immun

237 ow that CVB3 targets actively proliferating (bromodeoxyuridine+, Ki67+) cells in the SVZ, including t

238 We also assessed the number of bromodeoxyuridine labeled dividing glial cells in the PF

239 l technique employing immunoprecipitation of bromodeoxyuridine labeled nascent DNA followed by bisulf

240 Here, we show that bromodeoxyuridine-labeled and doublecortin-positive cell

241 nto anagen growth, confirmed by retention of bromodeoxyuridine-labeled bulge stem cells within the ha

242 Molecular combing of bromodeoxyuridine-labeled DNA revealed that once the Orc

243 and restitution was determined by assessing bromodeoxyuridine-labeled enterocytes along the crypt-vi

244 ctors increased the number of proliferating (bromodeoxyuridine-labeled) satellite cells in proximal a

245 Using in vivo bromodeoxyuridine labeling and in vitro functional assay

246 However, proliferation measured by in vivo bromodeoxyuridine labeling did not decline.

247 Bromodeoxyuridine labeling experiments show that lack of

248 s of epigenetic repressive marks, can retain bromodeoxyuridine labeling for a long time, and have col

249 s significantly increased liver mass and the bromodeoxyuridine labeling index compared with mice give

250 Bromodeoxyuridine labeling of dividing cells in 2-month-

251 Bromodeoxyuridine labeling of proliferating cells in the

252 Prox-1 immunohistochemistry and pulse-chase bromodeoxyuridine labeling showed that progenitors migra

253 nd ES cell-derived cardiomyocytes based on 5-bromodeoxyuridine labeling was similar, and immunocytoch

254 Colorectal tumor number and bromodeoxyuridine labeling were determined in Rosa26-Fox

255 cells using sucrose gradient sedimentation, bromodeoxyuridine labeling, chromatin immunoprecipitatio

256 Bromodeoxyuridine labeling, followed by immunoprecipitat

257 Bromodeoxyuridine labeling, in situ hybridization, and i

258 cell counting, cell proliferation assay, and bromodeoxyuridine labeling.

259 idine-labeled cells and confocal analysis of bromodeoxyuridine labeling.

260 However, pulse-chase 5-bromodeoxyuridine-labeling assay revealed that the senes

261 tate tumorigenesis lastingly coexistent with bromodeoxyuridine-labeling neoplastic lesions, revealing

262 escence showed a 95% co-localization of anti-bromodeoxyuridine labelling with apoptotic markers, demo

263 own that accumulation of recently recruited (bromodeoxyuridine(+) MAC387(+)) monocytes is associated

264 ar and paraventricular zones, the density of bromodeoxyuridine-, NeuN-, and doublecortin-labeled cell

265 Analysis by bromodeoxyuridine-nuclear labeling showed decreased inco

266 Intensity ratios of binucleated CPCs with bromodeoxyuridine of >/=70:30 between daughter nuclei in

267 i67), maturation (doublecortin) or survival (bromodeoxyuridine) of new adult-born hippocampal neurons

268 In addition, some GBCs retain bromodeoxyuridine or ethynyldeoxyuridine for an extended

269 or without a running wheel and injected with bromodeoxyuridine or retrovirus to label newborn cells.

270 A greater percentage of SMMs was bromodeoxyuridine positive (SMMs versus LBMs: 3.1% versu

271 rophages derived from circulating monocytes (bromodeoxyuridine positive [BrdU(+)] CD163(+)), suggesti

272 l proliferation (400 +/- 81 vs. 2630 +/- 390 bromodeoxyuridine-positive cells mm(-2) in controls, P <

273 Teduglutide increased bromodeoxyuridine-positive cells vs untreated controls b

274 euron-specific nuclear protein)-positive and bromodeoxyuridine-positive cells.

275 enesis evident by the reduction in number of bromodeoxyuridine-positive, Ki-67(+), and doublecortin(+

276 anti-phospho-Histone H3 immunoreactivity and bromodeoxyuridine pulse labelling.

277 Prior to tail loss, we performed a bromodeoxyuridine pulse-chase experiment and found that

278 Bromodeoxyuridine pulse-chase experiments with short sur

279 Utilizing in vivo imaging and bromodeoxyuridine pulse-chase experiments, we have analy

280 ectron microscopy, immunohistochemistry, and bromodeoxyuridine pulse-chase experiments.

281 Pulse-labeling of progenitors with bromodeoxyuridine showed that, as with surgical bulb rem

282 Application of bromodeoxyuridine significantly reduced cell damage, all

283 liferation and apoptosis were assessed using bromodeoxyuridine staining and terminal deoxynucleotidyl

284 Bromodeoxyuridine staining of papillomas and adjacent ep

285 -systolic pressure, right ventricular dP/dt, bromodeoxyuridine staining, or pulmonary artery medial w

286 h muscle cell proliferation as determined by bromodeoxyuridine staining.

287 chromatids was documented by clonal assay of bromodeoxyuridine-tagged hCSCs.

288 lated by cautery and animals were exposed to bromodeoxyuridine then examined following short (4-hour)

289 aily injections of the cell birthdate marker bromodeoxyuridine throughout puberty (postnatal day 28-4

290 current study, we used in vivo labeling with bromodeoxyuridine to characterize the kinetics of naive,

291 Cells were labeled with bromodeoxyuridine to detect proliferation, and indirect

292 f acetaminophen administered coincident with bromodeoxyuridine to load possible hepatic stem cells in

293 Bromodeoxyuridine uptake assay showed that cerebral hypo

294 Cell proliferation was measured by bromodeoxyuridine uptake.

295 trating T-cell proliferation was measured by bromodeoxyuridine uptakes, whereas their apoptosis was q

296 The thymidine analogue bromodeoxyuridine was administered to assess the degree

297 abeling of mitotic cells in the hippocampus, bromodeoxyuridine was injected into the peritoneal cavit

298 One month after irradiation, bromodeoxyuridine was injected intraperitoneally for sev

299 tibility to the thymine nucleoside analogue, bromodeoxyuridine, was reduced.

300 portion of newly generated oligodendrocytes (bromodeoxyuridine+) were PPAR-delta+.